N
ALNY icon

Nuveen’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nuveen’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-31,000
Closed -$5K – 3414
2021
Q2 		$5K Buy
+31,000
New +$4.54M ﹤0.01% 3302

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's ALNY Position: Q1 2026 in Review

Nuveen reduced its Alnylam Pharmaceuticals (ALNY) stake by 43% in Q1 2026, selling an estimated $82.9M and leaving 322,232 shares worth $107M. The position accounts for 0.03% of the portfolio, ranked #383.

Nuveen first reported a position in ALNY in Q3 2013 and has held it in 35 quarters since. The position peaked at $3.32B in Q3 2022. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Nuveen held 322,232 shares of Alnylam Pharmaceuticals worth $107M as of Q1 2026.
  • Nuveen sold 243,557 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $82.9M.
  • Alnylam Pharmaceuticals made up 0.03% of Nuveen's portfolio in Q1 2026, its #383 holding.
  • Nuveen first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 35 quarters since.
  • Nuveen's Alnylam Pharmaceuticals position peaked at $3.32B in Q3 2022.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.